Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
This study is investigating a treatment called tralokinumab for adults who have moderate to severe eczema (atopic dermatitis) affecting their genital region. Eczema in this sensitive area can be particularly challenging, and this research aims to understand how well tralokinumab helps improve symptoms and patients' overall well-being. They will be looking at changes in participants' symptoms using special scoring systems and surveys, as well as non-invasive imaging techniques. The study involves 30 patients who are already starting tralokinumab as part of their regular care. Over 52 weeks, researchers will collect information during routine check-ups to see if this treatment makes a noticeable difference for people living with this specific type of eczema.
De un vistazo
¿De qué trata este estudio?
This study is designed to understand how a medicine called tralokinumab works for people who have moderate to severe eczema, specifically when it affects their genital area. Eczema, also known as atopic dermatitis, can be very uncomfortable, and when it affects sensitive areas like the genitals, it can be particularly distressing and impact daily life. Tralokinumab is a treatment already used for eczema, but this study focuses on its effects on eczema in this specific body region.
The main idea behind this research is to see if tralokinumab can significantly improve the symptoms of genital eczema and help people feel better overall. The researchers will be using special ways to measure how severe the eczema is, as well as asking participants about their symptoms and quality of life through surveys. They also plan to use advanced non-invasive imaging techniques, which are like special cameras that can look at the skin without touching it, to track changes over time. By doing this, they hope to get a clear picture of how effective tralokinumab is for this specific type of eczema.
This is an important study because it focuses on a condition that can be very private and difficult to talk about, yet it significantly affects the lives of those who experience it. Understanding how tralokinumab helps in this specific area could lead to better treatment options and improved quality of life for many people.
Puntos clave
- Focuses on tralokinumab for eczema affecting the genital area.
- Aims to improve symptoms and quality of life.
- Involves adults (18+) with moderate to severe eczema.
- Participation involves routine check-ups over 52 weeks.
- You would already be starting this treatment as part of your care.
- Your medical care is not affected if you withdraw.
¿Quién puede ser elegible?
To be part of this study, you need to be an adult (at least 18 years old). You must also have been diagnosed with moderate to severe eczema (atopic dermatitis) that affects your genital area. Importantly, you would already be starting treatment with tralokinumab because your doctor has decided it's the right course of action for you, based on standard guidelines, even before you consider joining the study.
There are also some reasons why you couldn't join. For example, if you are currently pregnant or breastfeeding, this study would not be suitable for you. Also, if you're already taking part in another study that involves new, unapproved medications, you wouldn't be able to join this one. Finally, if your eczema doesn't affect your genital area, this particular study isn't for you.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tienes 18 años o más?
- Do you have moderate to severe eczema that affects your genital area?
- Has your doctor already decided you should start treatment with tralokinumab?
- ¿No estás embarazada ni amamantando?
- Are you NOT currently in another study testing a new, unapproved medicine?
¿En qué consiste la participación?
If you decide to take part in this study, you'll be treated with tralokinumab as part of your normal care, following the usual instructions for the medication. Over 52 weeks (about a year), researchers will collect information during your regular doctor's visits. These visits are usually at the start of your treatment, then at weeks 4, 16, 24, and 52. During these visits, your doctor will assess your eczema using special scoring systems and you might fill out some questionnaires about your symptoms and how you're feeling. They may also use non-invasive imaging (like a special camera) to look at your skin. Your participation will mainly involve these routine check-ups and assessments, which are part of your ongoing care.
Riesgos y beneficios potenciales
Ubicaciones (2)
- Department of Dermatology of the University Hospital AugsburgCódigo postal verificadoAugsburg, Germany· Reclutamiento
- CCIM, Institut für Entzündungsmedizin UKSH LübeckCódigo postal verificadoLübeck, Germany· Reclutamiento
Preguntas comunes
What is tralokinumab?
Tralokinumab is a medicine used to treat eczema (atopic dermatitis).
Will I get a new medicine if I join the study?
No, you will be receiving tralokinumab as part of your regular medical treatment, not as an experimental drug within the study.
¿Cuánto tiempo durará el estudio?
The study will follow your progress for about 52 weeks, or one year.
Do I have to go to extra appointments for this study?
The information for the study will be collected during your routine doctor appointments for your eczema treatment.
What are 'non-invasive imaging techniques'?
These are special ways to look at your skin, like using a camera, without actually touching or harming it.
Cómo obtener más información
Inga Brouer
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.